FULL ESTIMATED COST	28.79	195.94
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-4.50	-4.50

STN INTERNATIONAL LOGOFF AT 10:24:03 ON 29 AUG 2006

```
* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *
=>Uploading C:\Program Files\Stnexp\Queries\10737309.str
```





```
chain nodes :
7  8  9  10  11  12  13  16
ring nodes :
1  2  3  4  5  6
chain bonds :
2-8  5-7  7-9  9-11  9-16  10-11  11-13  12-13
ring bonds :
1-2  1-6  2-3  3-4  4-5  5-6
exact/norm bonds :
2-8  5-7  7-9  9-11  9-16  10-11  11-13  12-13
normalized bonds :
1-2  1-6  2-3  3-4  4-5  5-6
isolated ring systems :
containing 1 :


G1:H,Ak

Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  8:CLASS  9:CLASS  10:CLASS
11:CLASS  12:Atom  13:CLASS  16:CLASS



L1      STRUCTURE UPLOADED

=> dis l1
L1 HAS NO ANSWERS
L1              STR
```




```
G1 H,Ak

Structure attributes must be viewed using STN Express query preparation.
```

```
=> s l1 sam
L2             3 SEA SSS SAM L1

=> s l1 full
L3            38 SEA SSS FUL L1

=> file caplus
=> s l3
L4             6 L3

=> s l4 and pd<dec 2002
      22748392 PD<DEC 2002
                  (PD<20021200)
L5             4 L4 AND PD<DEC 2002

=> dis l5 1-4 bib abs hitstr

L5   ANSWER 1 OF 4  CAPLUS  COPYRIGHT 2006 ACS on STN
AN   2003:473270  CAPLUS Full-text
DN   139:36444
TI   Preparation of substituted ureas as neuropeptide Y5 receptor antagonists
IN   Greenlee, William J.; Huang, Ying; Kelly, Joseph M.; McCombie, Stuart W.;
     Stamford, Andrew W.; Wu, Yusheng
PA   Schering Corporation, USA
SO   U.S. Pat. Appl. Publ., 108 pp., Cont.-in-part of U.S. Ser. No. 950,908.
     CODEN: USXXCO
DT   Patent
LA   English
FAN.CNT 2
     PATENT NO.          KIND   DATE        APPLICATION NO.         DATE
     ---------------     ----   --------    --------------------    --------
PI   US 2003114517        A1    20030619    US 2002-96390           20020312
     US 6894063           B2    20050517
     US 2002165223        A1    20021107    US 2001-950908          20010912 <--
     US 2005038100        A1    20050217    US 2004-933016          20040901
PRAI US 2000-232255P      P     20000914
     US 2001-950908       A2    20010912
     US 2002-96390        A3    20020312
OS   MARPAT 139:36444
GI
```



I



II



III



IV



V



VI

AB The title compds. [I; Y = II, III; R1 = H, alkyl; R2 = H, alkyl, cycloalkyl, etc.; R3 = IV, V, etc.; j = 0-2; k = 1-2; l = 0-2; m = 0-2; p = 1-3; r = 1-3; R4 = H, OH, halo, etc.; R5 = H, halo, OH, etc.; R6 = alkylSO2, cycloalkylSO2, heteroarylalkyl, etc.;], useful as neuropeptide Y5 receptor antagonists for treating obesity, hyperphagia, type II diabetes, insulin resistance, and hypertension, were prepared E.g., a multi-step synthesis of VI, was given. For the compds. I, a range of neuropeptide Y5 receptor binding activity from about 0.2 nM to about 500 nM was observed Methods of preparing pharmaceutical formulations comprising one or more such compds. I were claimed.

IT 405056-07-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted ureas as neuropeptide Y5 receptor antagonists)

RN 405056-07-7 CAPLUS

CN Urea, N'-(3',5'-difluoro[1,1'-biphenyl]-4-yl)-N-[1-(5-hydroxy-2-pyridinyl)-4-piperidinyl]-N-methyl- (9CI) (CA INDEX NAME)



RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2002:220568 CAPLUS Full-text

DN 136:263169

TI Preparation of Substituted ureas as neuropeptide Y5 receptor antagonists

IN Greenlee, William J.; Huang, Ying; Kelly, Joseph M.; McCombie, Stuart W.; Stamford, Andrew W.; Wu, Yusheng

PA Schering Corporation, USA

SO PCT Int. Appl., 101 pp.
CODEN: PIXXD2

DT Patent

LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002022592	A2	20020321	WO 2001-US28324	20010912 <--
	WO 2002022592	A3	20020627		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2422013	AA	20020321	CA 2001-2422013	20010912 <--
	AU 2001094547	A5	20020326	AU 2001-94547	20010912 <--
	EP 1322628	A2	20030702	EP 2001-975194	20010912
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2004509108	T2	20040325	JP 2002-526845	20010912
PRAI	US 2000-232255P	P	20000914		
	WO 2001-US28324	W	20010912		

OS MARPAT 136:263169
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. [I; A = Q, Q1; R1 = H, F, Cl, CF3, OH; R2 = H, F, Cl, CF3, CN, OCH3, OH; R3 = H, F, Cl, CF3, OCF3, CN, OCH2C6H5, OH; R4 = H, F, Cl; X = NH, NCH3; n = 0, 1, 2; Y = NR5, C:NOH; R5 = SO2CH3, SO2(CH2)2CH3, cyclopropylmethyl, 3-pyridyl, 2-pyridyl, 2-thiazolyl, 2-pyrimidyl, 1-oxo-3-pyridyl, SO2NH2, CH2CONH2, CONH2, NHSO2CH3, SO2(CH2)2OH, C(:NCN)NHCH3, C(:NCN)SCH3, 3-pyridylcarbonyl, cyclobutylcarbonyl, cyclopentylcarbonyl, CON(CH3)2, cyclohexyl; R6 = H, F, Br, Cl, OCH3, OH; R7 = H, F, Cl, OCH3; etc.], stereoisomers, N-oxides, pharmaceutically acceptable salts or hydrates, and prodrugs are disclosed as neuropeptide Y5 receptor antagonists. Method of treating obesity, hyperphagia, type II diabetes, insulin resistance, and hypertension involving title compds. I are claimed. Thus, the title compound II was prepared from N-tert-butoxycarbonyl-4-piperidone, 4-bromophenyl isocyanate, 2-fluorophenylboronic acid, and methanesulfonyl chloride in multiple steps.

IT 405056-07-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted ureas as neuropeptide Y5 receptor antagonists)

RN 405056-07-7 CAPLUS

CN Urea, N'-(3',5'-difluoro[1,1'-biphenyl]-4-yl)-N-[1-(5-hydroxy-2-pyridinyl)-4-piperidinyl]-N-methyl- (9CI) (CA INDEX NAME)



L5 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1989:90608 CAPLUS Full-text
DN 110:90608
TI Fruit thinning agents containing pyrazoles
IN Kato, Shozo; Noma, Yutaka; Igami, Satoyoshi
PA Tokuyama Soda Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 27 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 63174905	A2	19880719	JP 1987-4945	19870114 <--
JP 07106964	B4	19951115		
PRAI JP 1987-4945		19870114		

OS MARPAT 110:90608
GI For diagram(s), see printed CA Issue.
AB Fruit thinning agents contg. title compds. I [R = H, alkyl, (substituted) Ph; R1-R5 = H, halo, (substituted) alkyl, alkoxy, alkylthio, alkoxyalkyl, OH, NO2, cyano; R1R2 forms ring; R6 = H, (substituted) alkyl, (substituted) Ph, (substituted) pyridyl; A = CH,N; n ≥ 0] as active ingredients are described. A solution of 5-amino-1,3-dimethylpyrazole in C6H6 was treated with 2,4-MeClC6H3OCHMeCOCl to give 84.8% N-pyrazolylpropanamide derivative II, which at 200 ppm showed fruit thinning to 23.8% in mandarin orange. A wettable powder was formulated containing II 10, polyoxyethylene nonylphenyl ether 2, clay 40, and zeolite 48 weight parts.
IT 118912-52-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as fruit thinning agent)
RN 118912-52-0 CAPLUS
CN Propanamide, 3-(2,4-dichlorophenoxy)-N-[1-(5-hydroxy-2-pyridinyl)-3,5-dimethyl-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



L5 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1987:576028 CAPLUS Full-text
DN 107:176028
TI Preparation of [(phenoxyalkanoyl)amino]pyrazole derivatives as herbicides, fungicides and bactericides
IN Kato, Shozo; Takematsu, Tetsuo; Igami, Satoyoshi; Ogasawara, Masaru
PA Tokuyama Soda Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 18 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 62138475	A2	19870622	JP 1985-277887	19851212 <--
	JP 05080469	B4	19931109		
PRAI	JP 1985-277887		19851212		

GI



I



II

AB The title compds. I [R1-R5 = H, halo, (un)substituted alkyl, alkoxy(alkyl), alkylthio, OH, NO2, cyano, or R1R2 being adjacent and completing a fused ring; R6 = (un)substituted alkyl, Ph or pyridyl; n = integer], useful as herbicides, fungicides and bactericides, were prepared A solution of 0.0042 mmol 2,4-Cl2C6H3OCH2COCl in benzene was added dropwise to a solution of 0.0032 mmol 5-amino-1,3-dimethylpyrazole and 0.0042 mmol Et3N in benzene and the mixture was stirred overnight to give 0.85 g a pyrazole derivative II (R7 = H, R8 = Me). In preemergence period, I at 100g/10 are controlled by 90-100% various weeds, e.g., Scirpus juncoides. II (R7 = Cl, R8 = 3,4-dichlorophenyl) in vitro is active against fungi, e.g., Pellicularia sasaki and a bacterium, Staphylococcus aureus.

IT 110731-75-4P
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as herbicide, fungicide and bactericide)
RN 110731-75-4 CAPLUS
CN Acetamide, 2-(2,4-dichlorophenoxy)-N-[1-(5-hydroxy-2-pyridinyl)-3,5-dimethyl-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



=> s l4 not l5
L6 2 L4 NOT L5

=> dis l6 1-2 bib abs

L6 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2006:238237 CAPLUS Full-text
DN 144:311912
TI Preparation of arylpyridines as inhibitors of hedgehog signalling.
IN Gunzner, Janet; Sutherlin, Daniel; Stanley, Mark; Bao, Liang; Castanedo, Georgette; Lalonde, Rebecca; Wang, Shumei; Reynolds, Mark; Savage, Scott; Malesky, Kimberly; Dina, Michael
PA Genentech, Inc., USA; Curis Incorporation
SO PCT Int. Appl., 256 pp.

CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2006028958	A2	20060316	WO 2005-US31284	20050902
WO 2006028958	A3	20060413		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

US 2006063779	A1	20060323	US 2005-217663	20050902
PRAI US 2004-607367P	P	20040902		

OS MARPAT 144:311912
GI



I

AB Title compds. [I; A = carbocyclyl, heterocyclyl; X = alkylene, NR4CO, NR4CS, NR4SO2, NR4PO(OH), etc.; R1 = (substituted) alkyl, carbocyclyl, heterocyclyl; R2 = halo, OH, (substituted) alkyl, acyl, alkoxy; R3 = halo, OH, CO2H, (substituted) alkyl, acyl, alkoxy, alkoxycarbonyl, carbamoyl, alkylthio, sulfinyl, sulfonyl, carbocyclyl, heterocyclyl; R4 = H, alkyl; m, n = 0-3], were prepared for treatment of cancer (no data). Thus, N-[4-chloro-3-(pyridin-2-yl)phenyl]-6-chloro-3-carboxamide and 2-morpholinoethylamine were heated in BuOH in a sealed tube to give 6-(2-morpholinoethylamino)-N-[4-chloro-3-(pyridin-2-yl)phenyl]-6-chloro-3- carboxamide.

L6 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:531358 CAPLUS Full-text
DN 141:89014
TI Preparation of pyridylcyclohexyl phenylpropanamide derivatives as NR2B receptor antagonists
IN Kawai, Makoto; Nakamura, Hiroshi; Shimokawa, Hirohisa
PA Pfizer Japan Inc., Japan; Pfizer Inc.
SO PCT Int. Appl., 91 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004054579	A1	20040701	WO 2003-IB5757	20031205

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,

```
            CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,
            GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,
            LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ,
            OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
            TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
        RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
            BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
            ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,
            TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
    CA 2510322          AA    20040701    CA 2003-2510322        20031205
    AU 2003303042       A1    20040709    AU 2003-303042         20031205
    EP 1575586          A1    20050921    EP 2003-813240         20031205
        R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
           IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
    BR 2003017409       A     20051108    BR 2003-17409          20031205
    JP 2006511528       T2    20060406    JP 2004-560052         20031205
    US 2004152715       A1    20040805    US 2003-737309         20031216
PRAI US 2002-434361P    P     20021217
    WO 2003-IB5757      W     20031205
OS  MARPAT 141:89014
GI
```



I



II

AB Title compds. I [wherein R2 = H or OH; or R forms a covalent bond with ring A; R3 = H or alkyl; R4 = (un)substituted (hetero)aryl; R5 = OH or alkylsulfonylamino; R6 = H, halo, alkylalkoxy; A = cycloalkylene; X = a covalent bond, alkylene, (hetero)alkenylene, etc.; Z = C or N; and pharmaceutically acceptable ester or salts thereof] were prepared as. For example, II•HCl was given in 5-step synthesis starting from trans-4-aminocyclohexanol and 3-phenylpropanoic acid. I showed Ki values from 2.7 μM to 8.9 μM with respect to inhibition of binding at the NR2B receptor. Thus, I and their pharmaceutical compns. are useful for the treatment of disease conditions caused by over activation of NMDA NR2B receptor such as pain, or the like in mammals.

```
RE.CNT  5     THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT


=> log
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:y
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                   ENTRY    SESSION
```